RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

Status Active, not recruiting

Clinical Trial Summary

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: - Rituximab - Utomilumab - Avelumab

Clinical Trial Description

This research study is a Phase 1 clinical trial. Phase 1 clinical trials test the safety of an investigational intervention and also try to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. Utomilumab and avelumab are drugs which may stimulate the immune system against tumor cells. Because they activate the immune system, they are sometimes called immunotherapy drugs. The FDA (the U.S. Food and Drug Administration) has not approved utomilumab or avelumab for treatment of this cancer. Rituximab is approved by the FDA (the U.S. Food and Drug Administration) as a treatment option for this disease. The purpose of this research is to learn about the effects of combining the immunotherapy drugs utomilumab and avelumab with rituximab in follicular lymphoma. The investigators hope to learn how safe the combinations of treatments are for participants with follicular lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03636503
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	October 30, 2018
Completion date	October 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Completed	`NCT00001512` - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines	Phase 1
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Active, not recruiting	`NCT03078855` - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma	Phase 3
Active, not recruiting	`NCT03245021` - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A	Phase 1
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Active, not recruiting	`NCT04082936` - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT02213263` - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)	Phase 3
Completed	`NCT01691898` - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	Phase 1/Phase 2
Terminated	`NCT03585725` - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma	Early Phase 1
Terminated	`NCT00772668` - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL	N/A
Recruiting	`NCT02892695` - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	Phase 1/Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Terminated	`NCT02204982` - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma	Phase 3
Terminated	`NCT00850499` - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab	Phase 2
Completed	`NCT02536664` - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated	`NCT00475332` - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar	Phase 2
Terminated	`NCT00136591` - A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma	Phase 2
Not yet recruiting	`NCT06068881` - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	Phase 2
Completed	`NCT04034056` - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)